Microorganisms

US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic

Retrieved on: 
Monday, July 20, 2020
Bacteria, Epsilonproteobacteria, Organisms, Microorganisms, Drug Safety, Food and Drug Administration, Escherichia coli, ETEC, Campylobacter, Investigational New Drug

The FDA were recently provided a Pre- Investigational New Drug (IND) package for the new Hyper-immune therapeutic which specifically targets Campylobacter jejuni capsule and Enterotoxigenic Escherichia coli (ETEC) colonization factor antigen 1.

Key Points: 
  • The FDA were recently provided a Pre- Investigational New Drug (IND) package for the new Hyper-immune therapeutic which specifically targets Campylobacter jejuni capsule and Enterotoxigenic Escherichia coli (ETEC) colonization factor antigen 1.
  • Following FDA review the agency provided a written response to the non-clinical questions posed in the briefing documentation as well as providing additional guidance and comments to support the planned IND submission.
  • This is an important milestone in the development of any new drug for therapeutic evaluation.
  • The company is also please to inform shareholders that the manufacturing program is proceeding as planned.

Insights on the Meningococcal Vaccine Global Market to 2026 - Opportunity Analysis and Industry Forecast

Retrieved on: 
Thursday, July 16, 2020
Bacteria, Microorganisms, Microbiology, Vaccination, RTT, Vaccines, Neisseria meningitidis, Neisseriales, Pathogenic bacteria, Meningococcal vaccine, Vaccine

DUBLIN, July 16, 2020 /PRNewswire/ -- The "Meningococcal Vaccine Market by Serogroup, Vaccine Type and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 16, 2020 /PRNewswire/ -- The "Meningococcal Vaccine Market by Serogroup, Vaccine Type and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026" report has been added to ResearchAndMarkets.com's offering.
  • Rise in immunization programs worldwide is the major factor that boost the growth of the meningococcal vaccine market.
  • Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the meningococcal vaccine market growth during the forecast period.
  • The global meningococcal vaccine market is segmented on the basis of serotype, vaccine types, and end user.

Worldwide Meningococcal Vaccine Industry to 2026 - Increase in Healthcare Spending Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, July 13, 2020
Infectious diseases, Pharmaceutical, Health, Bacteria, Microorganisms, Microbiology, Vaccination, Vaccine, Virology, Meningococcal vaccine, Neisseria meningitidis

Rise in immunization programs worldwide is the major factor that boost the growth of the meningococcal vaccine market.

Key Points: 
  • Rise in immunization programs worldwide is the major factor that boost the growth of the meningococcal vaccine market.
  • Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the meningococcal vaccine market growth during the forecast period.
  • The global meningococcal vaccine market is segmented on the basis of serotype, vaccine types, and end user.
  • Region wise, North America was the major shareholder and accounted for 49.84% of the meningococcal vaccine market share in 2018.

Nalco Water Launches Innovative Rapid Bio Intelligence Aerobic Bacteria Test Kit for Cooling Water Management

Retrieved on: 
Thursday, June 25, 2020
Building Systems, Chemicals, Plastics, Commercial Building & Real Estate, Construction & Property, Energy, Manufacturing, Technology, Environment, Agriculture, Natural Resources, Science, Software, Utilities, Mobile, Wireless, Research, Legionellales, Microbiology, Microorganisms, Industrial hygiene, Gram-negative bacteria, Legionella, Pathogenic bacteria, Nalco Holding Company, Bacteria, Ecolab

To help ensure optimal performance, Nalco Water, an Ecolab company, has introduced Rapid Bio Intelligence, a total aerobic bacteria test kit that radically simplifies water chemistry testing and compliance for cooling water systems.

Key Points: 
  • To help ensure optimal performance, Nalco Water, an Ecolab company, has introduced Rapid Bio Intelligence, a total aerobic bacteria test kit that radically simplifies water chemistry testing and compliance for cooling water systems.
  • Nalco Waters Rapid Bio Intelligence is a mobile app-driven test kit to monitor cooling water quality with quick and reliable results.
  • The Rapid Bio Intelligence solution consists of three components:
    Test kit determines the total amount of bacteria present in a water sample, in as little as 15 minutes*.
  • www.ecolab.com
    * The Rapid Bio Intelligence test is not strain-specific and does not measure Legionella bacteria.

COVID-19 Impact and Recovery Analysis- Veterinary Clostridium Vaccine Market 2020-2024 | Dependency on Livestock Products to Boost Growth | Technavio

Retrieved on: 
Wednesday, June 10, 2020
Agriculture, Natural Resources, Health, Veterinary, Pharmaceutical, Microbiology, Microorganisms, Organisms, Clostridiaceae, Clostridium, Gram-positive bacteria, Pathogenic bacteria, Vaccine, Clostridial vaccine

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Market estimates include pre- and post-COVID-19 impact on the Veterinary Clostridium Vaccine Market Download free sample report
    The market is concentrated, and the degree of concentration will accelerate during the forecast period.
  • Dependency on livestock products has been instrumental in driving the growth of the market.
  • https://www.technavio.com/report/report/veterinary-clostridium-vaccine-m...
    Veterinary Clostridium Vaccine Market 2020-2024: Segmentation
    Veterinary Clostridium Vaccine Market is segmented as below:

BioHiTech Enters Into Agreement to Distribute Altapure High-Level Disinfectant Technology That Can Effectively Kill Bacteria, Fungus, C.Difficile Spores, and Viruses Such as Coronavirus 2 (SARS-CoV-2)

Retrieved on: 
Tuesday, June 2, 2020
Bacteria, Microorganisms, Clostridiaceae, Gram-positive bacteria, Microbiology, C. Diff, Clostridioides difficile, Diarrhea, Clostridium difficile, Disinfectant, Clostridium

We look forward to working together with the team at Altapure to begin to pursue opportunities to help our customers thrive with a new eye towards safety as our country and the rest of the world begins to reopen for business."

Key Points: 
  • We look forward to working together with the team at Altapure to begin to pursue opportunities to help our customers thrive with a new eye towards safety as our country and the rest of the world begins to reopen for business."
  • auris and Clostridium difficile (C. difficile).
  • Altapure is committed to providing its customers with the highest quality products and processes in the marketplace that are safe to use and are environmentally friendly.
  • All of Altapure's products are engineered, manufactured, and assembled in the U.S.
    "We are excited to establish this relationship with BioHiTech to expand the distribution reach of our state-of-the-art high-level disinfection technologies," said Carl L. Ricciardi, co-founder and CEO of Altapure.

Anlit Rolls out New Portfolio of Immune-boosting Products in Tasty Delivery Platform

Retrieved on: 
Tuesday, June 2, 2020
Bacteria, Medical specialties, Microorganisms, Probiotics, Bacteriology, Digestive system, Lactobacillaceae, Bifidobacteriales, Bifidobacterium animalis, Lactobacillus acidophilus, Bifidobacterium, Nutraceutical

Anlit, with well-established expertise in the development of breakthrough delivery systems for probiotics and dietary supplements, incorporates nutraceuticals in flavorful, easy to enjoy gummies and chewable formats tailored for private label.

Key Points: 
  • Anlit, with well-established expertise in the development of breakthrough delivery systems for probiotics and dietary supplements, incorporates nutraceuticals in flavorful, easy to enjoy gummies and chewable formats tailored for private label.
  • "Much of our efforts at Anlit are dedicated to bringing more appeal to the daily supplement routine for kids, adults, seniors, and other pill-fatigued consumers," says David Gabbay, V.P of Marketing at Anlit.
  • These new products come in a variety of flavors to address these different consumers' preferences."
  • Anlit's LLP immune probiotic bites are composed of two active probiotic strains, Bifidobacterium lactis (Bl-04) and Lactobacillus acidophilus (La-14).

Ondine Biomedical Demonstrates Rapid Elimination of Bacterium Causing Flesh-Eating Disease

Retrieved on: 
Thursday, May 7, 2020
Bacteria, Microorganisms, Streptococcaceae, Organisms, Gram-positive bacteria, Pathogenic bacteria, Scarlet fever, Streptococcus pyogenes, Streptococcus, Antimicrobial resistance, Coccus

Ondine is developing a rapid, easy-to-use Photodisinfection approach to topical decolonization of S. pyogenes in order to reduce amputations, morbidity and mortality rates in these seriously ill patients.

Key Points: 
  • Ondine is developing a rapid, easy-to-use Photodisinfection approach to topical decolonization of S. pyogenes in order to reduce amputations, morbidity and mortality rates in these seriously ill patients.
  • According to the CDC, Streptococcus pyogenes (Group A Streptococcus) is a beta-hemolytic bacterium that can cause many different infections ranging from minor illnesses to deadly diseases.
  • Ondine Biomedical Inc. is certified woman-owned business dedicated to the development of treatment and prevention therapies for a broad-spectrum of multidrug-resistant bacterial, viral and fungal infections.
  • Angelika Vance Ondine Biomedical Inc. 604.838.2702 [email protected]

Coronavirus risk may depend on throat bacteria, according to inBiome group study

Retrieved on: 
Tuesday, May 5, 2020
Microbiology, Branches of biology, Microorganisms, Bacteriology, Microbiomes, Coronaviridae, Animal virology, Coronavirus, Microbiota

AMSTERDAM, May 5, 2020 /PRNewswire/ -- Dutch researchers today revealed findings from a collaborative study showing a potential link between the bacteria in a person's throat, known as the throat microbiome, and infection by coronavirus.

Key Points: 
  • AMSTERDAM, May 5, 2020 /PRNewswire/ -- Dutch researchers today revealed findings from a collaborative study showing a potential link between the bacteria in a person's throat, known as the throat microbiome, and infection by coronavirus.
  • Now, these researchers have shown that there is also a potential role of the throat microbiome in COVID-19.
  • Samples were collected from 135 patients using throat swabs; the same as used for coronavirus tests.
  • "More research is needed but this could provide a critical tool to understand people's risk of catching coronavirus, and maybe even a tool to prevent catching it at all."

New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized

Retrieved on: 
Monday, May 4, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Bacteria, Microorganisms, Medical specialties, Streptococcaceae, Gram-positive bacteria, Streptococcal infections, Infections specific to the perinatal period, Neonatology, Group B streptococcal infection, Streptococcus agalactiae, Streptococcus, Strep, the Study, Group B Streptococcus

Previous studies describing the burden of GBS infection in adults have primarily focused on invasive disease because existing surveillance systems rely on blood culture collection.

Key Points: 
  • Previous studies describing the burden of GBS infection in adults have primarily focused on invasive disease because existing surveillance systems rely on blood culture collection.
  • In the new study, however, non-invasive disease was 34 times more common than invasive disease, suggesting that adult GBS burden is considerably greater than previously recognized.
  • These new data suggest that the burden of GBS infection is considerably greater than previously recognized in earlier surveillance studies that only focused on invasive disease, said Julio Ramirez, M.D., Chief of the Division of Infectious Diseases at the University of Louisville.
  • Bacteria called Group B Streptococcus or Streptococcus agalactiae (Group B strep, GBS) commonly live in peoples gastrointestinal and genital tracts.